Modality
Bispecific Ab
MOA
ALKi
Target
AHR
Pathway
mTOR
NMOSD
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
~May 2018
→ ~Aug 2019
Phase 3
Nov 2019
→ Nov 2031
Phase 3Current
NCT04974132
857 pts·NMOSD
2019-11→2031-11·Recruiting
857 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-125.6y awayPh3 Readout· NMOSD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
Catalysts
Ph3 Readout
2031-11-12 · 5.6y away
NMOSD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04974132 | Phase 3 | NMOSD | Recruiting | 857 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA |